Showing results (81-90 of 193) with videos related to
Sort By:
Pageof 20
Therapeutic Drug Monitoring|June 17, 2006
Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteersFrieder Kees, Michael Bucher, Frank Schweda, et al.European Journal of Clinical Pharmacology|July 11, 2006
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled studyDagmar Busse, Silke Templin, Gerd Mikus, et al.Clinical Pharmacokinetics|March 5, 2019
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator DrugsGerd Mikus, Kathrin I Foerster, Marlene Schaumaeker, et al.Journal of Clinical Pharmacology|December 15, 2010
Daily honey consumption does not change CYP3A activity in humansLeonie Fetzner, Jürgen Burhenne, Johanna Weiss, et al.British Journal of Clinical Pharmacology|April 4, 2017
Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokineticsNicolas Hohmann, Rebecca Kreuter, Antje Blank, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 26, 2019
A follow-up report on potential drug interactions with clementines: Two single case experiments show no effect on CYP3A-dependent midazolam clearanceNicolas Hohmann, Gerd Mikus, Walter Emil Haefeli, et al.Clinical Pharmacokinetics|May 30, 2016
Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of VoriconazoleNicolas Hohmann, Franziska Kocheise, Alexandra Carls, et al.Danish Medical Journal|April 30, 2016
The CYTONOX trialChristina Gade, Gerd Mikus, Hanne Rolighed Christensen, et al.European Journal of Clinical Pharmacology|September 24, 2008
High absolute bioavailability of methylene blue given as an aqueous oral formulationIngeborg Walter-Sack, Jens Rengelshausen, Heike Oberwittler, et al.Journal of Clinical Pharmacology|August 14, 2013
Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activityFelicitas Stoll, Jürgen Burhenne, Berthold Lausecker, et al.Pageof 20